Abstract
Direct inhibition of blood coagulation factors such as thrombin, factor VIIa, and factor Xa has shown great promise for treating thrombosis disorders. Inhibitors of these serine proteases have been designed, synthesized, and evaluated. Small molecule thrombin inhibitors typically contain P1-P2-P3 components targeting the active binding site. Structure optimizations on the P1 position and the P3 position have been done extensively, but the P2 position has not been as thoroughly studied as the other positions. Thrombin inhibitors with a rigid bicyclic P2 unit are interesting compounds with a more defined conformation. Aeruginosins are a family of naturally occurring small molecules that exhibit serine protease inhibition activities; their structures are typically tetrapeptides with an unusual bicyclic amino acid core structure occupying the P2 position. About 21 compounds sharing the same core structure have been isolated and identified so far, and their analogs have also been synthesized. In this review, the Structure Activity Relationship (SAR) of these compounds against thrombin and other serine proteases and their potential as antithrombotic agents will be discussed. The binding modes to thrombin and other factors of the coagulation cascade and the preparation of the aeruginosin core structure will be summarized. Besides the aeruginosin family, the SAR of other small molecule serine protease inhibitors with a rigid bicyclic P2 unit will also be covered.
Keywords: Aeruginosin, Thrombin Inhibitor, Bicyclic Amino acids
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title: Aeruginosin Analogs and Other Compounds with Rigid Bicyclic Structure as Potential Antithrombotic Agents
Volume: 7 Issue: 2
Author(s): Guijun Wang and Navneet Goyal
Affiliation:
Keywords: Aeruginosin, Thrombin Inhibitor, Bicyclic Amino acids
Abstract: Direct inhibition of blood coagulation factors such as thrombin, factor VIIa, and factor Xa has shown great promise for treating thrombosis disorders. Inhibitors of these serine proteases have been designed, synthesized, and evaluated. Small molecule thrombin inhibitors typically contain P1-P2-P3 components targeting the active binding site. Structure optimizations on the P1 position and the P3 position have been done extensively, but the P2 position has not been as thoroughly studied as the other positions. Thrombin inhibitors with a rigid bicyclic P2 unit are interesting compounds with a more defined conformation. Aeruginosins are a family of naturally occurring small molecules that exhibit serine protease inhibition activities; their structures are typically tetrapeptides with an unusual bicyclic amino acid core structure occupying the P2 position. About 21 compounds sharing the same core structure have been isolated and identified so far, and their analogs have also been synthesized. In this review, the Structure Activity Relationship (SAR) of these compounds against thrombin and other serine proteases and their potential as antithrombotic agents will be discussed. The binding modes to thrombin and other factors of the coagulation cascade and the preparation of the aeruginosin core structure will be summarized. Besides the aeruginosin family, the SAR of other small molecule serine protease inhibitors with a rigid bicyclic P2 unit will also be covered.
Export Options
About this article
Cite this article as:
Wang Guijun and Goyal Navneet, Aeruginosin Analogs and Other Compounds with Rigid Bicyclic Structure as Potential Antithrombotic Agents, Cardiovascular & Hematological Agents in Medicinal Chemistry 2009; 7 (2) . https://dx.doi.org/10.2174/187152509787847092
DOI https://dx.doi.org/10.2174/187152509787847092 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
Call for Papers in Thematic Issues
Medicinal Plants with Beneficial Properties on Diabetes and Hypertension
Diabetes and hypertension are real scourges of the 21st century. It is imperative to act in order to find innovative solutions to this problem. Taking medications such as hypoglycemic and antihypertensive drugs may aggravate certain underlying comorbidities, such as chronic kidney disease and cardiovascular disease. This significant drawback therefore requires ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Nutraceuticals for Metabolic Syndrome Management: From Laboratory to Benchside
Current Vascular Pharmacology Advances in Dermoepidermal Skin Substitutes for Diabetic Foot Ulcers
Current Vascular Pharmacology Renin Inhibition as a New Strategy to Combat Cardiovascular Disease
Current Hypertension Reviews Stenting and Prevention of Ischemic Stroke
Current Drug Targets Antithrombotic Treatment after Atrial Fibrillation Ablation
Current Pharmaceutical Design COVID-19 and Neurology: An Emerging Association
Infectious Disorders - Drug Targets The Wnt Pathway: Emerging Anticancer Strategies
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Intravenous Implanted Neural Stem Cells Migrate to Injury Site, Reduce Infarct Volume, and Improve Behavior after Cerebral Ischemia
Current Neurovascular Research Promising Anti-Fibrotic Approaches for Future Treatment of Systemic Sclerosis
Current Rheumatology Reviews Role of Sympathetic Nerve Activity in Obesity, Hypertension and Metabolic Syndrome
Current Hypertension Reviews Treatment of Tachycardia in Hypertension: Where Do We Stand Now?
Current Hypertension Reviews Frequency Domain Mapping of Atrial Fibrillation - Methodology, Experimental Data and Clinical Implications
Current Cardiology Reviews The Impact of Alexithymia on Anxiety Disorders: a Review of the Literature
Current Psychiatry Reviews Limonene Enhances the In Vitro and In Vivo Permeation of Trimetazidine Across a Membrane-Controlled Transdermal Therapeutic System
Current Drug Delivery MK-0626, A Dipeptidyl Peptidase-4 Inhibitor, Improves Neovascularization by Increasing Both the Number of Circulating Endothelial Progenitor Cells and Endothelial Nitric Oxide Synthetase Expression
Current Medicinal Chemistry Activity-dependent Synaptic Plasticity and Metaplasticity in Spinal Motor Networks
Current Pharmaceutical Design Epigenetics in the Cerebrovascular System: Changing the Code without Altering the Sequence
Current Neurovascular Research Heart Failure Models: Traditional and Novel Therapy
Current Vascular Pharmacology Detection of Obstructive Sleep Apnea Using Internet of Things: A Review
International Journal of Sensors, Wireless Communications and Control Experimental Animal Models: Tools to Investigate Antidiabetic Activity
Current Pharmaceutical Design